Literature DB >> 22076805

A search for SNCA 3' UTR variants identified SNP rs356165 as a determinant of disease risk and onset age in Parkinson's disease.

Lucía F Cardo1, Eliecer Coto, Lorena de Mena, René Ribacoba, Oswaldo Lorenzo-Betancor, Pau Pastor, Lluis Samaranch, Ignacio F Mata, Marta Díaz, Germán Moris, Manuel Menéndez, Ana I Corao, Victoria Alvarez.   

Abstract

Alpha-synuclein gene (SNCA) polymorphisms have been associated with the common sporadic form of Parkinson's disease (PD). We searched for DNA variants at the SNCA 3' UTR through single strand conformation analysis and direct sequencing in a cohort of Spanish PD patients and controls. We have genotyped the rs356165 SNCA 3' UTR polymorphism in a total of 1,135 PD patients and 772 healthy controls from two Spanish cohorts (Asturias and Navarre). We identified six SNCA 3' UTR variants. Single nucleotide polymorphism (SNP) rs356165 was significantly associated with PD risk in the Spanish cohort (p = 0.0001; odd ratio = 1.37, 95%CI = 1.19-1.58). This SNP was also significantly associated with early age at onset of PD. Our work highlights rs356165 as an important determinant of the risk of developing PD and early age at onset and encourages future research to identify a functional effect on SNCA expression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22076805     DOI: 10.1007/s12031-011-9669-1

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  26 in total

1.  Molecular biology. miRNAs in neurodegeneration.

Authors:  Sébastien S Hébert; Bart De Strooper
Journal:  Science       Date:  2007-08-31       Impact factor: 47.728

2.  Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease.

Authors:  R Krüger; W Kuhn; T Müller; D Woitalla; M Graeber; S Kösel; H Przuntek; J T Epplen; L Schöls; O Riess
Journal:  Nat Genet       Date:  1998-02       Impact factor: 38.330

3.  LRRK2 mutations are a common cause of Parkinson's disease in Spain.

Authors:  I F Mata; O A Ross; J Kachergus; C Huerta; R Ribacoba; G Moris; M Blazquez; L M Guisasola; C Salvador; C Martinez; M Farrer; V Alvarez
Journal:  Eur J Neurol       Date:  2006-04       Impact factor: 6.089

4.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

5.  Multiple regions of alpha-synuclein are associated with Parkinson's disease.

Authors:  Jakob C Mueller; Julia Fuchs; Anne Hofer; Alexander Zimprich; Peter Lichtner; Thomas Illig; Daniela Berg; Ullrich Wüllner; Thomas Meitinger; Thomas Gasser
Journal:  Ann Neurol       Date:  2005-04       Impact factor: 10.422

6.  Repression of alpha-synuclein expression and toxicity by microRNA-7.

Authors:  Eunsung Junn; Kang-Woo Lee; Byeong Seon Jeong; Teresa W Chan; Joo-Young Im; M Maral Mouradian
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-23       Impact factor: 11.205

7.  alpha-Synuclein promoter confers susceptibility to Parkinson's disease.

Authors:  Philippe Pals; Sarah Lincoln; Jonathan Manning; Michael Heckman; Lisa Skipper; Mary Hulihan; Marleen Van den Broeck; Tim De Pooter; Patrick Cras; Julia Crook; Christine Van Broeckhoven; Matt J Farrer
Journal:  Ann Neurol       Date:  2004-10       Impact factor: 10.422

8.  A single nucleotide polymorphism in the 3'UTR of the SNCA gene encoding alpha-synuclein is a new potential susceptibility locus for Parkinson disease.

Authors:  Sotiria Sotiriou; Gretchen Gibney; Andreas D Baxevanis; Robert L Nussbaum
Journal:  Neurosci Lett       Date:  2009-06-18       Impact factor: 3.046

9.  Genome-wide association study reveals genetic risk underlying Parkinson's disease.

Authors:  Javier Simón-Sánchez; Claudia Schulte; Jose M Bras; Manu Sharma; J Raphael Gibbs; Daniela Berg; Coro Paisan-Ruiz; Peter Lichtner; Sonja W Scholz; Dena G Hernandez; Rejko Krüger; Monica Federoff; Christine Klein; Alison Goate; Joel Perlmutter; Michael Bonin; Michael A Nalls; Thomas Illig; Christian Gieger; Henry Houlden; Michael Steffens; Michael S Okun; Brad A Racette; Mark R Cookson; Kelly D Foote; Hubert H Fernandez; Bryan J Traynor; Stefan Schreiber; Sampath Arepalli; Ryan Zonozi; Katrina Gwinn; Marcel van der Brug; Grisel Lopez; Stephen J Chanock; Arthur Schatzkin; Yikyung Park; Albert Hollenbeck; Jianjun Gao; Xuemei Huang; Nick W Wood; Delia Lorenz; Günther Deuschl; Honglei Chen; Olaf Riess; John A Hardy; Andrew B Singleton; Thomas Gasser
Journal:  Nat Genet       Date:  2009-11-15       Impact factor: 38.330

10.  Adenosine deamination in human transcripts generates novel microRNA binding sites.

Authors:  Glen M Borchert; Brian L Gilmore; Ryan M Spengler; Yi Xing; William Lanier; Debashish Bhattacharya; Beverly L Davidson
Journal:  Hum Mol Genet       Date:  2009-09-23       Impact factor: 6.150

View more
  19 in total

1.  Age at onset in LRRK2-associated PD is modified by SNCA variants.

Authors:  Teresa Botta-Orfila; Mario Ezquerra; Pau Pastor; Rubén Fernández-Santiago; Claustre Pont-Sunyer; Yaroslau Compta; Oswaldo Lorenzo-Betancor; Lluis Samaranch; Maria José Martí; Francesc Valldeoriola; Matilde Calopa; Manel Fernández; Miquel Aguilar; Oriol de Fabregas; Jorge Hernández-Vara; Eduard Tolosa
Journal:  J Mol Neurosci       Date:  2012-06-06       Impact factor: 3.444

2.  SNCA 3'UTR genetic variants in patients with Parkinson's disease and REM sleep behavior disorder.

Authors:  M Toffoli; E Dreussi; E Cecchin; M Valente; N Sanvilli; M Montico; S Gagno; M Garziera; M Polano; M Savarese; G Calandra-Buonaura; F Placidi; M Terzaghi; G Toffoli; G L Gigli
Journal:  Neurol Sci       Date:  2017-04-13       Impact factor: 3.307

3.  Variants in the 3'UTR of SNCA do not affect miRNA-433 binding and alpha-synuclein expression.

Authors:  Ina Schmitt; Ullrich Wüllner; Jan Pierre van Rooyen; Hassan Khazneh; Julian Becker; Alexander Volk; Christian Kubisch; Tim Becker; Vladimir S Kostic; Christine Klein; Alfredo Ramirez
Journal:  Eur J Hum Genet       Date:  2012-05-23       Impact factor: 4.246

Review 4.  Deregulation of α-synuclein in Parkinson's disease: Insight from epigenetic structure and transcriptional regulation of SNCA.

Authors:  Subhrangshu Guhathakurta; Eugene Bok; Baggio A Evangelista; Yoon-Seong Kim
Journal:  Prog Neurobiol       Date:  2017-04-23       Impact factor: 11.685

Review 5.  The unlikely partnership between LRRK2 and α-synuclein in Parkinson's disease.

Authors:  Noémie Cresto; Camille Gardier; Francesco Gubinelli; Marie-Claude Gaillard; Géraldine Liot; Andrew B West; Emmanuel Brouillet
Journal:  Eur J Neurosci       Date:  2018-10-24       Impact factor: 3.386

6.  Variants in GBA, SNCA, and MAPT influence Parkinson disease risk, age at onset, and progression.

Authors:  Albert A Davis; Kristin M Andruska; Bruno A Benitez; Brad A Racette; Joel S Perlmutter; Carlos Cruchaga
Journal:  Neurobiol Aging       Date:  2015-09-30       Impact factor: 4.673

7.  SNCA and mTOR Pathway Single Nucleotide Polymorphisms Interact to Modulate the Age at Onset of Parkinson's Disease.

Authors:  Rubén Fernández-Santiago; Núria Martín-Flores; Francesca Antonelli; Catalina Cerquera; Verónica Moreno; Sara Bandres-Ciga; Elisabetta Manduchi; Eduard Tolosa; Andrew B Singleton; Jason H Moore; María-Josep Martí; Mario Ezquerra; Cristina Malagelada
Journal:  Mov Disord       Date:  2019-06-24       Impact factor: 10.338

Review 8.  Decoding disease: from genomes to networks to phenotypes.

Authors:  Aaron K Wong; Rachel S G Sealfon; Chandra L Theesfeld; Olga G Troyanskaya
Journal:  Nat Rev Genet       Date:  2021-08-02       Impact factor: 53.242

9.  α-Synuclein genetic variants predict faster motor symptom progression in idiopathic Parkinson disease.

Authors:  Beate Ritz; Shannon L Rhodes; Yvette Bordelon; Jeff Bronstein
Journal:  PLoS One       Date:  2012-05-15       Impact factor: 3.240

Review 10.  A systematic review of associations between common SNCA variants and clinical heterogeneity in Parkinson's disease.

Authors:  Camilla Christina Pedersen; Johannes Lange; Marthe Gurine Gunnarsdatter Førland; Angus D Macleod; Guido Alves; Jodi Maple-Grødem
Journal:  NPJ Parkinsons Dis       Date:  2021-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.